The Aethlon Hemopuriﬁer®• Provides a
therapeutic ﬁltration mechanism to remove cancer exosomes from the circulatory system• Allows selective exosome capture via unique high-mannose signatures resident on exosome surfaces
Providing access to the entire
circulatory system• Exosomes can be accessed from entire circulatory system, which can pass through the Hemopuriﬁer® in as little as 15 minutes
This presentation contains forward-looking statements
within the meaning of the Private SecuritiesLitigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements besubject to the safe harbor created thereby. These statements are based on management’s currentexpectations and beliefs and are subject to a number of risks, uncertainties and assumptions that couldcause actual results to differ materially from those described. All statements, other than statements ofhistorical fact, are statements that could be deemed forward-looking statements, including the company’sability to successfully obtain FDA and other regulatory approvals for the sale of its products, thecapability of the Hemopuriﬁer® to reduce viral loads and other disease conditions or to identify or treatdisease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and theimpact that potential ability may have on disease conditions, and the company’s ability to raise capitalwhen needed. Some information in this presentation, or on which this presentation is based, has been obtained fromsources that Aethlon Medical, Inc., believes to be reliable and accurate. However, it has not beenindependently veriﬁed and no representation or warranty, express or implied, is made as to the accuracyor completeness of any information obtained from third parties. Such risks and uncertainties, including those discussed above, are more fully described in the Securitiesand Exchange Commission (SEC) reports ﬁled by Aethlon Medical, Inc., including its most recent annualreport on Form 10-K. This presentation speaks only as of its date, and the company disclaims any dutyto update the information herein. Further information is available by contacting the company or at thecompany’s website at www.aethlonmedical.com.